Head and Neck Squamous Cell Carcinoma CPG Mini Module - Selecting Appropriate Treatment Strategies for Recurrent/Metastatic HNSCC
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
Dan P. Zandberg, MD - UPMC Hillman Cancer Center presents a case of a 63-year-old man with metastatic squamous cell carcinoma (SCC), two years after undergoing a resection for teh SCC of the tongue. This presentation addresses teh current standard of care of SCC and the roles of PD-L1 testing when planning treatment for SCC. Insights from KEYNOTE-048 clinical trial, which compared the efficacies of immunotherapy, an immunotherapy/chemotherapy combination, adn the EXTREME regimen for treatment of recurrent/metastatic HNSCC are also provided. The mini module concludes with a panel discussion between Dr. Zandberg, Ezra Cohen, MD, FRCPSC, FASCO - UC San Diego, and Andrew G. Sikora, MD, PhD - The University of Texas MD Anderson Cancer Center about important factors to consider when planning treatment for patients with recurrent/metastatic HNSCC.
Run time: Approximately 16 minutes
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.